Intellia Therapeutics, Inc. — Institutional Ownership
Which tracked institutions hold NTLA, and how they changed the position last quarter. Latest holdings as of Mar 31, 2026. Source: SEC 13-F filings.
24
Funds holding
$409873820
Total value held
Buying
20 added/new · 2 reduced
| # | Institution | Value | Shares | Δ Shares | Change (QoQ) |
|---|---|---|---|---|---|
| 1 | Blackrock, Inc. | $155837437 | 12155806 | +1878957 | +18.28% |
| 2 | State Street Corp | $88748706 | 6922676 | +503840 | +7.85% |
| 3 | Regeneron Pharmaceuticals, Inc. | $47472396 | 3702995 | — | Held |
| 4 | Morgan Stanley | $26683520 | 2081397 | -246455 | -10.59% |
| 5 | Goldman Sachs Group Inc | $20874050 | 1628241 | +172622 | +11.86% |
| 6 | Bank Of America Corp /De/ | $17713432 | 1381703 | +139325 | +11.21% |
| 7 | Northern Trust Corp | $12387876 | 966293 | +93714 | +10.74% |
| 8 | Marex Group Plc | $7994552 | 623600 | — | NEW BUY |
| 9 | Raymond James Financial Inc | $7396243 | 576930 | +175269 | +43.64% |
| 10 | Royal Bank Of Canada | $5968000 | 465499 | — | NEW BUY |
| 11 | Bank Of New York Mellon Corp | $4204965 | 328000 | +13798 | +4.39% |
| 12 | Wells Fargo & Company/Mn | $3899341 | 433742 | -106073 | -19.65% |
| 13 | Invesco Ltd. | $3895277 | 433290 | +23870 | +5.83% |
| 14 | Citigroup Inc | $2078093 | 231156 | +141488 | +157.79% |
| 15 | Barclays Plc | $1887643 | 147242 | — | NEW BUY |
| 16 | Ameriprise Financial Inc | $1643639 | 128209 | +54683 | +74.37% |
| 17 | Janus Henderson Group Plc | $614569 | 47957 | — | NEW BUY |
| 18 | Sei Investments Co | $257629 | 20093 | — | NEW BUY |
| 19 | Prudential Financial Inc | $224735 | 17530 | — | NEW BUY |
| 20 | Pnc Financial Services Group, Inc. | $45537 | 3552 | +948 | +36.41% |
| 21 | Fifth Third Bancorp | $37858 | 2953 | — | NEW BUY |
| 22 | Us Bancorp \De\ | $7474 | 583 | +108 | +22.74% |
| 23 | Amalgamated Financial Corp. | $830 | 11420 | — | NEW BUY |
| 24 | Atlantic Union Bankshares Corp | $18 | 2 | — | Held |
Aggregated across tracked institutional filers. Reported quarterly on SEC Form 13-F and may lag. For research only — not investment advice.